Application claims compositions of “psilocybe-derived agent and a cannabis-derived agent”
”formulated in multiple layers to release the psilocybin-derived agent and the cannabis-derived agent at multiple different times, dosages and/or locations in a subject during dosing”
2/
Application asserts controlled release formulations of psilocybin + CBD can result in “multiple chemical-induced high/low shocks”
"useful in eliciting short or long term traumatic experience suppression in similar fashion to electroshock therapy without memory eradication”
US Patent No. 10,870,632 “Process For Producing An Extract Containing Tetrahydrocannabinol And Cannabidiol From Cannabis Plant Material, And Cannabis Extracts”
New patent application by Small Pharma published today.
The “invention provides compositions and methods which enable a finely tuned single dose to maintain a patient in full dissociation from the external world, referred to herein as ‘DMT space.’”
1/
In particular, the invention takes advantage of “the kinetic isotope effect” exhibited by deuterated DMT analogs “in order to modify, controllably, the pharmacokinetic profile of N,N-DMT, thereby permitting more flexible therapeutic application.”
“Deuterated” means that one or more hydrogen atoms in DMT are replaced by its heavier stable isotope deuterium. Because of the “kinetic isotope effect,” deuterated drugs may have significantly lower rates of metabolism and a longer half-life.